idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
01/24/2023 12:09

ERC Proof of Concept Grant for Anna Hirsch

Dr. Andreas Fischer Presse und Kommunikation
Helmholtz-Zentrum für Infektionsforschung

    HIPS scientist receives funding to develop new antibiotics

    The European Research Council (ERC) grants are among the most prestigious awards in the scientific community. Prof Anna Hirsch from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now succeeded in acquiring a coveted ERC grant for the second time. Under the "Proof of Concept" funding program, she will receive €150,000 to bring her basic research findings closer to a potential application. Thematically, Hirsch's project focuses on medicinal chemistry approaches to develop novel antibiotics against resistant bacteria.

    The COVID-19 pandemic has highlighted the importance of effective drugs to combat infectious diseases and has led to numerous innovations and developments in antiviral agents. At the same time, however, it may also have provided a significant boost to the spread of antibiotic resistance. This is because many of the patients infected with SARS-CoV-2 were treated with antibiotics as a precautionary measure to prevent additional bacterial infection - and the more frequently antibiotics are used, the greater the likelihood that resistance will develop. To counteract this trend, innovative antibiotics with previously unused mechanisms of action are urgently needed. Prof Anna Hirsch has set herself the task of developing precisely such active substances. Hirsch is head of the Department of Drug Design and Optimization at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), professor of medicinal chemistry at Saarland University and scientist in the research area "Novel Antibiotics" at the German Center for Infection Research (DZIF). HIPS is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

    As part of her 2018 ERC Starting Grant, Anna Hirsch has already succeeded in identifying a number of novel molecules that target previously unused structures in bacteria and thus represent a promising starting point for the development of resistance-breaking antibiotics. One of these target structures is a protein called DnaN. This protein is an essential part of the bacterial machinery responsible for repairing and producing new DNA. Thus, if the activity of DnaN is impaired, the affected bacteria can no longer reproduce. This makes DnaN an extremely attractive target for the development of new active substances. The ERC Proof of Concept funding now obtained will give Anna Hirsch the opportunity to further optimize her most promising drug candidate.

    "The goal is to improve our current best molecule to the point where we can nominate a preclinical candidate at the end of the project. For this, we rely on the already established structure-activity relationships and binding mode of our DnaN inhibitor. This is a very important step towards a potential application. Once this candidate is found, we can start testing and optimizing our compound for human application," says Hirsch. "Along the way, we are getting additional support from partners and mentors in the pharmaceutical industry. Such knowledge is invaluable in order to eventually come up with a product that can contribute to everyday clinical practice in a meaningful way." In addition to researchers from Anna Hirsch's department, scientists at HIPS, HZI and the Research Center Borstel have also been involved in the project.

    The managing director of HIPS, Prof Rolf Müller, is also enthusiastic about the renewed ERC funding: "A major problem in antibiotics research is that only insufficient funding is provided for the transition from basic research to application. We are all the more pleased that Anna Hirsch has now succeeded in acquiring such funding. Only a few scientists succeed in obtaining funding from one of the prestigious ERC programs during the course of their careers. The fact that Anna Hirsch has now achieved this for the second time makes us proud and shows that she is one of the top researchers in her field."

    The funding obtained by Hirsch comprises €150,000 and has a duration of 12 months. The project is expected to start in the second quarter of 2023.

    This press release is also available on our website: https://www.helmholtz-hzi.de/en/news-events/news/view/article/complete/erc-proof....

    Helmholtz Institute for Pharmaceutical Research Saarland:
    HIPS in Saarbrücken was founded in 2009 as a site of the Helmholtz Centre for Infection Research in collaboration with Saarland University. Researchers here are looking in particular for new active ingredients against infectious diseases, optimizing them for use in humans and investigating how they can best be transported to their site of action in the human body. http://www.helmholtz-hips.de

    Helmholtz Centre for Infection Research:
    Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases. http://www.helmholtz-hzi.de/en

    German Center for Infection Research
    At the German Center for Infection Research (DZIF), more than 500 scientists from 35 institutions nationwide jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. Their aim is to translate research results into clinical practice rapidly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostics and drugs in the fight against infections. http://www.dzif.de

    Contact for the media:
    Dr Yannic Nonnenmacher
    PR Manager HIPS
    +49 681 98806-4500
    yannic.nonnenmacher@helmholtz-hips.de


    Images

    Prof Anna Hirsch
    Prof Anna Hirsch
    Oliver Dietze
    HIPS/Oliver Dietze


    Criteria of this press release:
    Business and commerce, Journalists, Scientists and scholars, Students
    Biology, Chemistry, Medicine
    transregional, national
    Personnel announcements
    English


     

    Prof Anna Hirsch


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).